非结核分枝杆菌与其他呼吸道病原微生物合并感染的研究进展

doi:10.19982/j.issn.1000-6621.20240264

摘要/Abstract

摘要：

随着人口老龄化程度逐年上升,结构性肺病患者不断增多,非结核分枝杆菌肺病(non-tuberculous mycobacteria pulmonary disease, NTM-PD)的发病率呈现增高趋势。大多数NTM-PD患者发病时已存在基础肺病,常同时合并感染多种病原微生物,进一步增加了NTM病诊治和疗效判定的难度,合并感染成为导致NTM-PD治疗成功率低和复发率高的重要原因之一。作者通过检索相关文献,对NTM合并感染的研究进展进行综述,以丰富临床工作者对NTM-PD患者肺部合并感染的认识,研究临床干预策略。

关键词: 分枝杆菌感染, 非典型性细菌, 呼吸道感染, 研究

Abstract:

With the increasing aging of the population and the growing number of patients with structural lung diseases, the incidence of non-tuberculous mycobacteria pulmonary disease (NTM-PD) is on the rise. Most patients with NTM-PD have pre-existing underlying lung disease and are frequently co-infected with multiple pathogenic microorganisms, which further increases the difficulty of diagnosis and treatment of NTM disease as well as the evaluation of the efficacy of regimen. Co-infection is one of the major reasons for the low therapeutic success rate and high relapse rate. The authors reviewed the research progress of NTM co-infections by searching the relevant literature, in an attempt to enrich the understanding of pulmonary co-infections in patients with NTM-PD and to discuss their clinical intervention strategies.

Key words: Mycobacterium infections, Atypical bacterial forms, Respiratory tract infections, Research

中图分类号:

杜姗姗, 沙巍, 王丽. 非结核分枝杆菌与其他呼吸道病原微生物合并感染的研究进展[J]. 中国防痨杂志, 2024, 46(12): 1535-1540. doi: 10.19982/j.issn.1000-6621.20240264

Du Shanshan, Sha Wei, Wang Li. Research progress on co-infection of non-tuberculous mycobacteria and other respiratory pathogens[J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1535-1540. doi: 10.19982/j.issn.1000-6621.20240264

参考文献 46

[1]	Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis, 2014, 18(11):1370-1377. doi:10.5588/ijtld.14.0120. pmid: 25299873
[2]	罗雪娇, 沙巍. 《非结核分枝杆菌病诊断》解读. 结核与肺部疾病杂志, 2021, 2(2): 116-119. doi:10.3969/j.issn.2096-8493.2021.02.005.
[3]	Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review. Semin Respir Crit Care Med, 2018, 39(3): 336-342. doi:10.1055/s-0038-1660864. pmid: 30071548
[4]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
[5]	Fujita K, Ito Y, Hirai T, et al. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res, 2014, 1(1): e000050. doi:10.1136/bmjresp-2014-000050.
[6]	Urabe N, Sakamoto S, Sano G, et al. Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection. J Infect Chemother, 2018, 24(10): 822-827. doi:10.1016/j.jiac.2018.06.014.
[7]	Wang G, Stapleton JT, Baker AW, et al. Clinical Features and Treatment Outcomes of Pulmonary Mycobacterium avium-intracellulare Complex With and Without Coinfections. Open Forum Infect Dis, 2022, 9(8): ofac375. doi:10.1093/ofid/ofac375.
[8]	Ito M, Furuuchi K, Fujiwara K, et al. Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease. Respir Med, 2023, 219: 107417. doi:10.1016/j.rmed.2023.107417.
[9]	Takeda K, Imamura Y, Takazono T, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol, 2016, 54(2): 120-127. doi:10.1093/mmy/myv093. pmid: 26531100
[10]	Kamata H, Asakura T, Suzuki S, et al. Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. BMC Pulm Med, 2017, 17(1): 198. doi:10.1186/s12890-017-0544-x.
[11]	Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax, 2005, 60(12):1045-1051. doi:10.1136/thx.2005.046631. pmid: 16227333
[12]	Orme IM, Ordway DJ. Host response to nontuberculous mycobacterial infections of current clinical importance. Infect Immun, 2014, 82(9): 3516-3522. doi:10.1128/IAI.01606-13. pmid: 24914222
[13]	Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med, 2015, 36(1): 1-11. doi:10.1016/j.ccm.2014.10.001.
[14]	Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med, 2013, 187(12):1374-1381. doi:10.1164/rccm.201212-2197OC.
[15]	Zoumot Z, Boutou AK, Gill SS, et al. Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis. Respirology, 2014, 19(5):714-722. doi:10.1111/resp.12287. pmid: 24690015
[16]	Ishikawa S, Yano S, Kadowaki T, et al. Clinical analysis of non-tuberculous mycobacteriosis cases complicated with pulmonary aspergillosis. Kekkaku, 2011, 86(9):781-785.
[17]	Kunst H, Wickremasinghe M, Wells A, et al. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J, 2006, 28(2): 352-357. doi:10.1183/09031936.06.00139005. pmid: 16611651
[18]	Fayos M, Silva JT, López-Medrano F, et al. Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review. J Clin Med, 2022, 11(19): 5619. doi:10.3390/jcm11195619.
[19]	Furuuchi K, Ito A, Hashimoto T, et al. Risk stratification for the development of chronic pulmonary aspergillosis in patients with Mycobacterium avium complex lung disease. J Infect Chemother, 2018, 24(8): 654-659. doi:10.1016/j.jiac.2018.04.002. pmid: 29705392
[20]	Jhun BW, Jung WJ, Hwang NY, et al. Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. PLoS One, 2017, 12(11): e0188716. doi:10.1371/journal.pone.0188716.
[21]	Urabe N, Sakamoto S, Shimanuki Y, et al. Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation. BMC Pulm Med, 2022, 22(1): 157. doi:10.1186/s12890-022-01947-7.
[22]	Hsieh MH, Lin CY, Wang CY, et al. Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis. Infect Drug Resist, 2018, 11:1137-1143. doi:10.2147/IDR.S169789.
[23]	Böllert FG, Sime PJ, MacNee W, et al. Pulmonary Mycobacterium malmoense and aspergillus infection: a fatal combination?. Thorax, 1994, 49(5):521-522. doi:10.1136/thx.49.5.521. pmid: 8016779
[24]	Geurts K, Zweijpfenning SMH, Pennings LJ, et al. Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?. Eur Respir J, 2019, 54(1): 1900117. doi:10.1183/13993003.00117-2019.
[25]	Zhu YN, Xie JQ, He XW, et al. Prevalence and Clinical Characteristics of Nontuberculous Mycobacteria in Patients with Bronchiectasis: A Systematic Review and Meta-Analysis. Respiration, 2021, 100(12): 1218-1229. doi:10.1159/000518328.
[26]	Carazo-Fernández L, González-Cortés C, López-Medrano R, et al. Mycobacterium avium complex infected cells promote growth of the pathogen Pseudomonas aeruginosa. Microb Pathog, 2022, 166: 105549. doi:10.1016/j.micpath.2022.105549.
[27]	Birmes FS, Wolf T, Kohl TA, et al. Mycobacterium abscessus subsp. abscessus Is Capable of Degrading Pseudomonas aeruginosa Quinolone Signals. Front Microbiol, 2017, 8: 339. doi:10.3389/fmicb.2017.00339.
[28]	Déziel E, Gopalan S, Tampakaki AP, et al. The contribution of MvfR to Pseudomonas aeruginosa pathogenesis and quorum sensing circuitry regulation: multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-homoserine lactones. Mol Microbiol, 2005, 55(4): 998-1014. doi:10.1111/j.1365-2958.2004.04448.x.
[29]	Heeb S, Fletcher MP, Chhabra SR, et al. Quinolones: from antibiotics to autoinducers. FEMS Microbiol Rev, 2011, 35(2): 247-274. doi:10.1111/j.1574-6976.2010.00247.x.
[30]	Smalley NE, An D, Parsek MR, et al. Quorum Sensing Protects Pseudomonas aeruginosa against Cheating by Other Species in a Laboratory Coculture Model. J Bacteriol, 2015, 197(19): 3154-3159. doi:10.1128/JB.00482-15. pmid: 26195596
[31]	Costello A, Reen FJ, O’Gara F, et al. Inhibition of co-colonizing cystic fibrosis-associated pathogens by Pseudomonas aeruginosa and Burkholderia multivorans. Microbiology (Reading), 2014, 160(Pt 7):1474-1487. doi:10.1099/mic.0.074203-0.
[32]	Lee Y, Kim YJ, Lee JH, et al. TatC-dependent translocation of pyoverdine is responsible for the microbial growth suppression. J Microbiol, 2016, 54(2): 122-130. doi:10.1007/s12275-016-5542-9. pmid: 26832668
[33]	Bryant JM, Brown KP, Burbaud S, et al. Stepwise pathogenic evolution of Mycobacterium abscessus. Science, 2021, 372(6541): eabb8699. doi:10.1126/science.abb8699.
[34]	Rodríguez-Sevilla G, García-Coca M, Romera-García D, et al. Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model. Int J Med Microbiol, 2018, 308(3): 413-423. doi:10.1016/j.ijmm.2018.03.003. pmid: 29555180
[35]	Idosa AW, Wozniak DJ, Hall-Stoodley L. Surface Dependent Inhibition of Mycobacterium abscessus by Diverse Pseudomonas aeruginosa Strains. Microbiol Spectr, 2022, 10(6): e0247122. doi:10.1128/spectrum.02471-22.
[36]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1): 2000535. doi:10.1183/13993003.00535-2020.
[37]	Zhang J, Leifer F, Rose S, et al. Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages. Front Microbiol, 2018, 9: 915. doi:10.3389/fmicb.2018.00915. pmid: 29867826
[38]	Olivier KN, Griffith DE, Eagle G, et al. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med, 2017, 195(6): 814-823. doi:10.1164/rccm.201604-0700OC.
[39]	Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med, 2018, 198(12): 1559-1569. doi:10.1164/rccm.201807-1318OC.
[40]	中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识. 中华结核和呼吸杂志, 2018, 41(6): 409-446. doi:10.3760/cma.j.issn.1001-0939.2018.06.004.
[41]	He S, Guo Q, Zhao L, et al. Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity. Front Microbiol, 2022, 12: 779531. doi:10.3389/fmicb.2021.779531.
[42]	中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版). 中华结核和呼吸杂志, 2022, 45(8): 739-752. doi:10.3760/cma.j.cn112147-20220407-00290.
[43]	Takano K, Shimada D, Kashiwagura S, et al. Severe Pulmonary Mycobacterium abscessus Cases Due to Co-Infection with Other Microorganisms Well Treated by Clarithromycin and Sitafloxacin in Japan. Int Med Case Rep J, 2021, 14: 465-470. doi:10.2147/IMCRJ.S321969.
[44]	Sano C, Tatano Y, Shimizu T, et al. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents, 2011, 37(4): 296-301. doi:10.1016/j.ijantimicag.2010.12.014.
[45]	Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis, 1994, 18(2): 266. doi:10.1093/clinids/18.2.266.
[46]	Moon SM, Park HY, Jeong BH, et al. Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection. Antimicrob Agents Chemother, 2015, 59(1): 663-665. doi:10.1128/AAC.04075-14. pmid: 25313207